|1.||Levis, Mark: 7 articles (03/2011 - 05/2004)|
|2.||Small, Donald: 7 articles (03/2011 - 05/2004)|
|3.||Smith, B Douglas: 5 articles (03/2011 - 05/2004)|
|4.||Brodeur, Garrett M: 3 articles (12/2011 - 03/2010)|
|5.||Minturn, Jane E: 3 articles (12/2011 - 03/2010)|
|6.||Maris, John M: 3 articles (12/2011 - 03/2010)|
|7.||Sato, Takashi: 3 articles (03/2011 - 02/2010)|
|8.||Denmeade, Samuel R: 3 articles (09/2007 - 02/2002)|
|9.||Baer, Maria R: 2 articles (09/2015 - 03/2011)|
|10.||Hexner, Elizabeth O: 2 articles (09/2015 - 06/2008)|
01/01/2014 - "Our study indicated that lestaurtinib is highly potent against breast cancers as a mono-treatment agent. "
01/01/2005 - "While CEP-701 did not produce an objective tumor response in any patient, 7 of the 30 patients received treatment for 3 months or more, including 3 who were on study with stable disease for more than 6 months. "
03/01/2010 - "Lestaurtinib alone significantly inhibited tumor growth compared to vehicle-treated animals [P = 0.0004 for tumor size and P = 0.011 for event-free survival (EFS)]. "
06/30/1999 - "In addition, CEP-701 administration inhibited tumor cell invasion in the s.c. "
08/01/1999 - "Reductions in tumor growth volume of 50-70% relative to vehicle-treated controls were observed in xenografts responsive to CEP-701 administration. "
|2.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
05/15/2004 - "Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia."
03/24/2011 - "Overall, lestaurtinib treatment after chemotherapy did not increase response rates or prolong survival of patients with FLT3 mutant acute myeloid leukemia in first relapse. "
03/24/2011 - "We examined in vivo FLT3 inhibition in acute myeloid leukemia patients treated with chemotherapy followed by the FLT3 inhibitor lestaurtinib, comparing newly diagnosed acute myeloid leukemia patients with relapsed patients. "
01/01/2014 - "After initial screening, we performed further cellular and molecular analysis on lestaurtinib, which is an orally bioavailable multikinase inhibitor and has been used in clinical trials for myeloproliferative disorders and acute myelogenous leukemia. "
01/01/2015 - "Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia."
|3.||Prostatic Neoplasms (Prostate Cancer)
08/01/2001 - "These in vivo studies demonstrated that treatment with CEP-701 inhibits the growth of both rodent and human prostate cancers, without being toxic to the normal tissue including the host prostate. "
08/01/2001 - "In the present studies, the consequences of CEP-701 inhibition of these trk signaling survival pathways were tested in vivo using both rat (R3327 AT 6.3 and H) and human (TSU-pr1 and CWR-22Rv1) prostatic cancer models. "
09/01/2007 - "Therefore, the effectiveness of CEP-701 as treatment for prostate cancer has not been adequately tested. "
09/01/2007 - "CEP-701 is a potent inhibitor of trk receptors that causes cell death in prostate cancer (PC) models. "
08/01/2001 - "This regimen maintains CEP-701 tumor tissue concentrations of 25-50 nM. Such chronic dosing increased (P < 0.001) the median survival of rats bearing the slow growing H prostate cancers from 408 days (395-432 days, 95% confidence interval) for the vehicle group (n = 18) to 566 days (497-598 days, 95% confidence interval) for the CEP-701-treated group (n = 24)."
03/01/2010 - "We wanted to determine if the Trk-selective inhibitor lestaurtinib had therapeutic efficacy in a preclinical neuroblastoma model. "
10/01/2011 - "Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study."
10/01/2011 - "Lestaurtinib was well tolerated in patients with refractory neuroblastoma, and a dose level sufficient to inhibit TrkB activity was established. "
10/01/2011 - "Patients with refractory high-risk neuroblastoma received lestaurtinib twice daily for 5 days out of seven in 28-day cycles, starting at 70% of the adult recommended Phase 2 dose. "
03/01/2010 - "We performed intervention trials of lestaurtinib alone or in combination with other agents in TrkB-overexpressing neuroblastoma xenograft models. "
01/01/2005 - "A phase I clinical trial in patients with advanced carcinomas was conducted using the orally available neurotrophin receptor-linked tyrosine kinase receptor inhibitor, CEP-701. "
06/30/1999 - "The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness."
|3.||tyrosine receptor (receptor, tyrosine)
|4.||Brain-Derived Neurotrophic Factor (BDNF)
|6.||K 252 (K252a)
|7.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)